+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
ID06888960

Study to Evaluate the Safety and Tolerability of CC312 for Adults with Refractory Autoimmune Diseases Using Intravenous Treatment

Led by CytoCares Inc · Updated on 2025-09-17

18

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of CC312, a trispecific T cell engager targeting CD19, CD3, and CD28, in adult patients with relapsed and refractory autoimmune diseases. This early-phase, open-label trial aims to assess pharmacokinetics and preliminary effectiveness while carefully managing risks like cytokine release syndrome through a priming dose followed by therapeutic doses. The study uses a 33 dose escalation design across three dose groups involving 9 to 18 participants. After a 28-day screening period, eligible participants receive CC312 intravenously starting with a guided priming dose on Day -3, followed by safety assessments on Day -1. Therapeutic doses are then administered on Days 1, 4, 8, 11, 15, 18, 22, and 25, with ongoing safety and tolerability evaluations at each infusion. This design helps identify the optimal dose while monitoring for adverse effects. Participants undergo baseline assessments and biological sample collection before dosing. Throughout the study, safety data including dose-limiting toxicities and adverse events are tracked for up to two years. Additional measures include pharmacokinetic analyses, immune cell counts, disease activity scores, and advanced cellular analyses. Female and male participants of reproductive potential must agree to contraception and reproductive restrictions during and after treatment. The total study duration includes screening, guided dose, therapeutic dosing, and long-term safety monitoring.

CONDITIONS

Brief Title

Safety Study of CC312 in Autoimmune Disease Patients

Research Team

C

CEO

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here